FDA Pulls Cancer Drug Approvals Due to Safety Concerns
06/08/2022
FDA Pulls Cancer Drug Approvals Due to Safety Concerns Safety concerns have prompted the FDA to withdraw approval of umbralisib (Ukoniq) On June 1, 2022, the U.S. Food and Drug Administration withdrew its approval for the cancer medicine umbralisib (Ukoniq) permitted for the treatment of adults with marginal zone lymphoma (MZL) and follicular lymphoma (FL), the agency announced in a safety commun...
View More